Celon Pharma S.A. has finalised another part of the phase I clinical trial for its esketamine-based drug. The centre conducting the study confirmed that the course of this part of the trial is in accordance with the assumptions defined in the clinical protocol.
Maciej Wieczorek, PhD, President of the Board of Celon Pharma S.A.: Participants received different doses of the drug, in inhalation sequences, determined based on an analysis of safety results and pharmacokinetic parameters obtained in the first part of the phase I trial. In the next part, we will assess the safety of repeated administration of fixed doses of the drug to participants, in specific inhalation sequences, as compared to placebo. The course of the trial reflects the assumptions we have adopted in the field of patient safety in full, as defined in the clinical protocol. In accordance with the adopted time schedule, we should finalise the entire phase I in May 2018.